These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 1830925)

  • 1. No relevance to Parkinson's.
    Hefti F; Denton TL; Beck KD; Michel PP
    Nature; 1991 Aug; 352(6336):573. PubMed ID: 1830925
    [No Abstract]   [Full Text] [Related]  

  • 2. Striatal molecular mechanisms and motor dysfunction in Parkinson's disease.
    Chase TN; Konitsiotis S; Oh JD
    Adv Neurol; 2001; 86():355-60. PubMed ID: 11553996
    [No Abstract]   [Full Text] [Related]  

  • 3. The role of glutamate in the pathophysiology of Parkinson's disease.
    Blandini F; Greenamyre JT; Nappi G
    Funct Neurol; 1996; 11(1):3-15. PubMed ID: 8936453
    [No Abstract]   [Full Text] [Related]  

  • 4. Methylphenylpyridium ion (MPP+) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon.
    Sawada H; Shimohama S; Tamura Y; Kawamura T; Akaike A; Kimura J
    J Neurosci Res; 1996 Jan; 43(1):55-62. PubMed ID: 8838574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "Ottorino Rossi" Award 2000. New targets for therapy in Parkinson's disease: pathogenesis and pathophysiology.
    Greenamyre JT
    Funct Neurol; 2000; 15(2):67-80. PubMed ID: 10916718
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopamine-acetylcholine-glutamate interactions in the striatum. A working hypothesis.
    Di Chiara G; Morelli M
    Adv Neurol; 1993; 60():102-6. PubMed ID: 8093571
    [No Abstract]   [Full Text] [Related]  

  • 8. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan.
    Montastruc JL; Fabre N; Rascol O; Senard JM; Blin O
    Mov Disord; 1994 Mar; 9(2):242-3. PubMed ID: 8196695
    [No Abstract]   [Full Text] [Related]  

  • 9. Parkinson's disease and milacemide.
    Youdim MB
    Mov Disord; 1994 Sep; 9(5):585-6. PubMed ID: 7990857
    [No Abstract]   [Full Text] [Related]  

  • 10. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease.
    Koutsilieri E; Riederer P
    Parkinsonism Relat Disord; 2007; 13 Suppl 3():S329-31. PubMed ID: 18267259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease.
    Hirsch E; Graybiel AM; Agid YA
    Nature; 1988 Jul; 334(6180):345-8. PubMed ID: 2899295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease.
    Leaver KR; Allbutt HN; Creber NJ; Kassiou M; Henderson JM
    Clin Exp Pharmacol Physiol; 2008 Nov; 35(11):1388-94. PubMed ID: 18785982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopamine transporter-mediated cytotoxicity of beta-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake.
    Storch A; Hwang YI; Gearhart DA; Beach JW; Neafsey EJ; Collins MA; Schwarz J
    J Neurochem; 2004 May; 89(3):685-94. PubMed ID: 15086525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ; Standaert DG
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renaissance of amantadine in the treatment of Parkinson's disease.
    Blanchet PJ; Metman LV; Chase TN
    Adv Neurol; 2003; 91():251-7. PubMed ID: 12442683
    [No Abstract]   [Full Text] [Related]  

  • 17. The visual system in Parkinson's disease.
    Bodis-Wollner I; Tagliati M
    Adv Neurol; 1993; 60():390-4. PubMed ID: 8420159
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical aspects of Parkinson's disease.
    Nagatsu T
    Adv Neurol; 1993; 60():165-74. PubMed ID: 8093575
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of 1-methyl-4-phenylpyridinium on radioligand binding to the NMDA receptor complex.
    Sundström E; Mo LL
    Res Commun Mol Pathol Pharmacol; 1995 May; 88(2):131-6. PubMed ID: 7670845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent progress in development of psychotropic drugs (3)--Antiparkinsonian agents applied in the treatment of Parkinson's disease or are under investigation for patients or model animals].
    Nomoto M
    Nihon Shinkei Seishin Yakurigaku Zasshi; 1996 Aug; 16(4):113-22. PubMed ID: 8905800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.